** Sera Prognostics Inc's SERA.O shares down 15.3% premarket to $3.77, over 1-yr low, after overnight follow-on priced
** Salt Lake City-based women's health firm late Mon announced 12.5 mln shares, including 11.25 mln pre-funded warrants, at $4 for $50 mln gross proceeds
** Offering price is 10.1% discount to last sale
** Co intends to use net offering proceeds to expand commercial infrastructure in the U.S., accelerate preparations for expansion in the European Union, fund additional studies to increase adoption of its blood test to predict preterm birth risks, PreTRM, including a potential submission to U.S. FDA for broad approval
** Jefferies, TD Cowen and William Blair are jt bookrunners, along with RBC
** Co has ~33.77 mln shares outstanding for market cap of ~$150 mln and ~28.6 mln shares of free float, per LSEG
** SERA shares, which have fallen 6 of the past 7 sessions, have declined 45% YTD through Mon close
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。